- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07942584
Intravenous Recombinant Human Prourokinase (rhPro-UK) for Acute Ischemic Stroke Within 4.5 to 24 Hours of Onset (PROST-3)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Standard-of-Care-Controlled Phase III Clinical Trial of Intravenous Recombinant Human Prourokinase (rhPro-UK) for the Treatment of Acute Ischemic Stroke Within 4.5 to 24 Hours of Symptom Onset
This is a multicenter, randomized, double-blind, double-dummy, standard-of-care-controlled Phase III clinical trial to evaluate the efficacy and safety of intravenous recombinant human prourokinase (rhPro-UK) in adult patients with acute ischemic stroke (AIS) within 4.5 to 24 hours of symptom onset, including wake-up stroke and unwitnessed stroke.Eligible patients with salvageable ischemic tissue confirmed by CT perfusion or MRI perfusion/diffusion imaging will be randomized in a 1:1 ratio to receive either intravenous rhPro-UK 35 mg plus oral aspirin enteric-coated tablet placebo, or intravenous rhPro-UK placebo plus oral aspirin enteric-coated tablets 100-300 mg (standard of care).The primary objective is to evaluate the efficacy of intravenous rhPro-UK compared with standard of care in achieving a favorable functional outcome, defined as a modified Rankin Scale (mRS) score of 0-1 at 90 days after treatment. A total of 978 participants (489 per arm) will be enrolled at multiple centers in China.
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
Study Design: This is a multicenter, randomized, double-blind, double-dummy, standard-of-care (SOC)-controlled Phase III trial conducted at multiple centers in China. Randomization is performed using a stratified block randomization method, stratified by planned mechanical thrombectomy (2 levels: yes; no), with participants assigned in a 1:1 ratio to the rhPro-UK group or the SOC group.Treatment: Eligible and randomized participants receive the assigned investigational product as soon as possible (actual treatment initiation must be >4.5 hours and <=24 hours after stroke onset). The rhPro-UK group receives an intravenous infusion of rhPro-UK 35 mg in normal saline (15 mg as a slow intravenous bolus over 3 minutes, followed by the remaining 20 mg by intravenous infusion/pump over 30 minutes), plus oral aspirin enteric-coated tablet placebo 100-300 mg at the start of thrombolysis. The SOC group receives an intravenous infusion of rhPro-UK placebo (same regimen) plus oral aspirin enteric-coated tablets 100-300 mg. All investigational products are administered once only; subsequent clinical antiplatelet therapy should be initiated no earlier than 24 hours after completion of the investigational product administration.Study Duration: The total duration of participation for each participant is approximately 90 days, including a screening period (pre-thrombolysis, -24 hours to 0 hour), a treatment period (thrombolysis, 0 hour), and a follow-up period (24 hours, 72 hours, Day 7, Day 30, and Day 90 after the start of thrombolysis).Statistical Considerations: The study hypothesis is based on the primary estimand. Null hypothesis H0: p1/p2 <= 1; alternative hypothesis H1: p1/p2 > 1, where p1 is the proportion of participants with an mRS score of 0-1 at 90 days in the rhPro-UK group and p2 is that in the SOC group. One interim analysis is planned, using the Lan-DeMets spending function with O'Brien-Fleming efficacy boundaries; the two-sided type I error is controlled at 0.003 for the interim analysis and 0.049 for the final analysis, maintaining an overall two-sided type I error of 0.05.Committees: An Academic Committee will be established before trial initiation to ensure the scientific feasibility of the protocol and standardization of trial conduct. An independent Clinical Events Committee (CEC) will adjudicate the type and drug-relatedness of all-cause death events within 7 days after treatment, as well as symptomatic intracranial hemorrhage (sICH). A Data Monitoring Committee (DMC) will convene regularly or as needed to perform unblinded sample size re-estimation, review safety data, and advise the sponsor on whether to continue, suspend, or stop the trial, or adjust the sample size.
Studietype
Inschrijving (Geschat)
Fase
- Fase 3
Contacten en locaties
Studiecontact
- Naam: Yongjun Wang, MD, PhD
- Telefoonnummer: +86 13911172565
- E-mail: Yongjunwang111@aliyun.com
Studie Contact Back-up
- Naam: Chunjuan Wang, MD, PhD
- Telefoonnummer: +86 18210100840
- E-mail: wangchunjuan@ncrcnd.org.cn
Studie Locaties
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China
- Beijing Tiantan Hospital, Capital Medical University
-
Contact:
- Yongjun Wang, MD, PhD
- Telefoonnummer: +86 13911172565
- E-mail: Yongjunwang111@aliyun.com
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Age >=18 years, male or female;
- Time from stroke symptom onset to planned thrombolysis >4.5 hours and <=24 hours (including wake-up stroke and unwitnessed stroke); the time of symptom onset is defined as the time the patient was last known to be well;
- Proximal or distal occlusion/stenosis of the internal carotid artery, middle cerebral artery, anterior cerebral artery, or posterior cerebral artery confirmed by CTA or MRA, identified as the culprit vessel responsible for the current acute ischemic stroke;
- Salvageable ischemic tissue demonstrated on CT perfusion (CTP) or MRI PWI/DWI sequences (infarct core volume <70 mL; hypoperfusion-to-infarct core mismatch ratio >=1.8; mismatch volume >=15 mL);
- NIHSS score of 6 to 25 (inclusive);
- Pre-stroke mRS score <2;
- No significant improvement in stroke clinical manifestations before treatment (as assessed by the investigator);
- The patient or his/her legally authorized representative is willing to participate in the trial and agrees to sign the informed consent form.
Exclusion Criteria:
- Unable to complete CTP/CTA or PWI/DWI/MRA examination;
- Large cerebral infarction indicated by CT/MRI (infarct area larger than one-third of the middle cerebral artery territory);
- Intracranial hemorrhage shown on CT/MRI (including parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural/epidural hematoma, etc.);
- Previous history of intracranial hemorrhage;
- Major head trauma or ischemic stroke within the past 3 months;
- Intracranial tumor or giant intracranial aneurysm;
- Intracranial or intraspinal surgery within the past 3 months;
- Gastrointestinal or urinary tract bleeding within the past 3 weeks;
- Major surgery or severe trauma within the past 2 weeks (as assessed by the investigator);
- Arterial puncture at a non-compressible site within the past 1 week;
- Active internal bleeding;
- Aortic arch dissection;
- Bacterial endocarditis or pericarditis;
- Hypertension remaining uncontrolled despite active antihypertensive therapy, with a post-treatment systolic blood pressure still >185 mmHg or diastolic blood pressure still >110 mmHg;
- Acute bleeding tendency, including platelet count <100 x 10^9/L;
- Treatment with low-molecular-weight heparin or heparin within 24 hours;
- Use of thrombin inhibitors or factor Xa inhibitors within the past 48 hours;
- Currently taking oral anticoagulants with prothrombin time (PT) >15 seconds or international normalized ratio (INR) >1.7;
- Seizure at stroke onset, or coexisting psychiatric disorder precluding compliance;
- Blood glucose <2.8 mmol/L (50 mg/dL) or >22.2 mmol/L (400 mg/dL);
- Severe hepatic insufficiency, including liver failure, cirrhosis, portal hypertension (esophageal varices), or active hepatitis;
- Severe renal insufficiency (eGFR <30 mL/min/1.73 m^2);
- Any terminal illness with a life expectancy of less than 1 year;
- Known hypersensitivity to rhPro-UK, the active ingredient of aspirin, or any other components of the investigational products;
- Pregnant or lactating women;
- Participation in another clinical trial within the past 1 month;
- Any condition that, in the opinion of the investigator, makes the patient unsuitable for participation in the trial;
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verviervoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: rhPro-UK Group
Participants receive an intravenous infusion of recombinant human prourokinase (rhPro-UK) 35 mg in normal saline (15 mg administered as a slow intravenous bolus over 3 minutes, followed by the remaining 20 mg administered by intravenous infusion/pump over the subsequent 30 minutes), plus oral aspirin enteric-coated tablet placebo 100-300 mg (at the investigator's discretion) at the start of thrombolysis. All investigational products are administered once only. |
rhPro-UK 35 mg dissolved in normal saline, administered intravenously as a single dose: 15 mg slow intravenous bolus over 3 minutes, followed by 20 mg intravenous infusion/pump over 30 minutes. Treatment initiation must be >4.5 hours and <=24 hours after stroke onset. Oral placebo matching aspirin enteric-coated tablets, 100-300 mg, administered once at the start of thrombolysis (dose at the investigator's discretion). |
|
Actieve vergelijker: Standard of Care (SOC) Group
Participants receive an intravenous infusion of rhPro-UK placebo in normal saline (same administration regimen as the rhPro-UK group), plus oral aspirin enteric-coated tablets 100-300 mg (at the investigator's discretion) at the start of thrombolysis. All investigational products are administered once only. |
Oral aspirin enteric-coated tablets 100-300 mg, administered once at the start of thrombolysis (dose at the investigator's discretion). Subsequent clinical antiplatelet therapy is initiated no earlier than 24 hours after completion of the investigational product administration. Placebo matching rhPro-UK for injection, dissolved in normal saline and administered intravenously with the same regimen as rhPro-UK (15 mg-equivalent slow intravenous bolus over 3 minutes, followed by 20 mg-equivalent intravenous infusion/pump over 30 minutes), single dose. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Proportion of Participants Achieving a Favorable Functional Outcome (mRS 0-1)
Tijdsspanne: 90 days after treatment
|
Description: Proportion of participants with a modified Rankin Scale (mRS) score of 0-1 at 90 days after treatment. |
90 days after treatment
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Distribution of mRS Scores
Tijdsspanne: 90 days after treatment
|
Distribution of modified Rankin Scale (mRS) scores at 90 days after treatment |
90 days after treatment
|
|
Proportion of Participants Achieving Functional Independence (mRS 0-2)
Tijdsspanne: 90 days after treatment
|
Proportion of participants with an mRS score of 0-2 at 90 days after treatment. |
90 days after treatment
|
|
Proportion of Participants With Early Neurological Improvement at 24 Hours
Tijdsspanne: 24 hours after treatment
|
Proportion of participants with a decrease of >=4 points in the National Institutes of Health Stroke Scale (NIHSS) score from baseline, or an NIHSS score <=1, at 24 hours after treatment. |
24 hours after treatment
|
|
Proportion of Participants With Neurological Improvement at Day 7
Tijdsspanne: 7 days after treatment
|
Proportion of participants with a decrease of >=4 points in NIHSS score from baseline, or an NIHSS score <=1, at 7 days after treatment. |
7 days after treatment
|
|
Change From Baseline in NIHSS Score at 24 Hours
Tijdsspanne: Baseline and 24 hours after treatment
|
Change in NIHSS score from baseline at 24 hours after treatment. |
Baseline and 24 hours after treatment
|
|
Change From Baseline in NIHSS Score at Day 7
Tijdsspanne: Baseline and 7 days after treatment
|
Change in NIHSS score from baseline at 7 days after treatment. |
Baseline and 7 days after treatment
|
|
Proportion of Participants With a Barthel Index of 95-100
Tijdsspanne: 90 days after treatment
|
Proportion of participants with a Barthel Index score of 95-100 at 90 days after treatment. |
90 days after treatment
|
|
Proportion of Participants Achieving Reperfusion at 24 Hours
Tijdsspanne: 24 hours after treatment
|
Proportion of participants achieving reperfusion at 24 hours after treatment, defined as a >90% reduction from baseline in the volume of tissue with tracer arrival time (Tmax) >6 seconds. |
24 hours after treatment
|
|
Proportion of Participants Achieving Good Reperfusion on Angiography Before Thrombectomy
Tijdsspanne: Before mechanical thrombectomy (Day 0)
|
Proportion of participants achieving good reperfusion, defined as an expanded Thrombolysis in Cerebral Infarction (eTICI) grade of 2b50 or higher, on angiography before thrombectomy (assessed only in participants undergoing mechanical thrombectomy). |
Before mechanical thrombectomy (Day 0)
|
|
Incidence of Symptomatic Intracranial Hemorrhage (sICH) per the SITS-MOST Definition
Tijdsspanne: Within 36 hours after treatment
|
Incidence of symptomatic intracranial hemorrhage as defined by the SITS-MOST criteria. |
Within 36 hours after treatment
|
|
Incidence of Symptomatic Intracranial Hemorrhage (sICH) per the ECASS III Definition
Tijdsspanne: Within 7 days after treatment
|
Incidence of symptomatic intracranial hemorrhage as defined by the ECASS III criteria. |
Within 7 days after treatment
|
|
Incidence of All-Cause Mortality Within 7 Days
Tijdsspanne: Within 7 days after treatment
|
Incidence of death from any cause within 7 days after treatment. |
Within 7 days after treatment
|
|
Incidence of All-Cause Mortality Within 90 Days
Tijdsspanne: Within 90 days after treatment
|
Within 90 days after treatment
|
|
|
Incidence of Major Bleeding Events Within 7 Days
Tijdsspanne: Within 7 days after treatment
|
Within 7 days after treatment
|
|
|
Incidence of Intracranial Hemorrhage Events Within 7 Days
Tijdsspanne: Within 7 days after treatment
|
Within 7 days after treatment |
Within 7 days after treatment
|
Medewerkers en onderzoekers
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- TSL-BIO2601-AIS24-Ⅲ
- NMPA IND No. (Andere identificatie: 2026LP02152)
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .